These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 27208385)

  • 1. Some augmentation strategies improve outcome but increase discontinuation in adults with treatment-resistant depression.
    Andrade C
    Evid Based Ment Health; 2016 May; 19(2):e7. PubMed ID: 27208385
    [No Abstract]   [Full Text] [Related]  

  • 2. Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).
    McAllister-Williams RH; Smith E; Anderson IM; Barnes J; Gallagher P; Grunze HC; Haddad PM; House AO; Hughes T; Lloyd AJ; McColl EM; Pearce SH; Siddiqi N; Sinha B; Speed C; Steen IN; Wainright J; Watson S; Winter FH; Ferrier IN
    BMC Psychiatry; 2013 Aug; 13():205. PubMed ID: 23914988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lithium or an atypical antipsychotic drug in the management of treatment-resistant depression: a systematic review and economic evaluation.
    Edwards SJ; Hamilton V; Nherera L; Trevor N
    Health Technol Assess; 2013 Nov; 17(54):1-190. PubMed ID: 24284258
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for the benefits of nonantipsychotic pharmacological augmentation in the treatment of depression.
    Chang CM; Sato S; Han C
    CNS Drugs; 2013 May; 27 Suppl 1():S21-7. PubMed ID: 23712796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lamotrigine augmentation in treatment-resistant unipolar depression: A comprehensive meta-analysis of efficacy and safety.
    Goh KK; Chen CH; Chiu YH; Lu ML
    J Psychopharmacol; 2019 Jun; 33(6):700-713. PubMed ID: 31081449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for depression.
    Med Lett Drugs Ther; 2016 Jul; 58(1498):85-90. PubMed ID: 27348144
    [No Abstract]   [Full Text] [Related]  

  • 8. What are the comparative benefits and harms of augmentation treatments in major depression?
    Shelton RC
    J Clin Psychiatry; 2015 Apr; 76(4):e531-3. PubMed ID: 25919851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment.
    Ball SG; Atkinson S; Sparks J; Bangs M; Goldberger C; Dubé S
    J Clin Psychopharmacol; 2015 Jun; 35(3):266-72. PubMed ID: 25815754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial.
    Miyaoka T; Kanayama M; Wake R; Hashioka S; Hayashida M; Nagahama M; Okazaki S; Yamashita S; Miura S; Miki H; Matsuda H; Koike M; Izuhara M; Araki T; Tsuchie K; Azis IA; Arauchi R; Abdullah RA; Oh-Nishi A; Horiguchi J
    Clin Neuropharmacol; 2018; 41(5):151-155. PubMed ID: 30234616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tianeptine combination for partial or non-response to selective serotonin re-uptake inhibitor monotherapy.
    Woo YS; Bahk WM; Jeong JH; Lee SH; Sung HM; Pae CU; Koo BH; Kim W
    Psychiatry Clin Neurosci; 2013 May; 67(4):219-27. PubMed ID: 23683152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjunctive medication strategies for treatment-resistant depression.
    Lam RW
    Can J Psychiatry; 2011 Jun; 56(6):315-6. PubMed ID: 21756444
    [No Abstract]   [Full Text] [Related]  

  • 13. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR).
    Kessler DS; MacNeill SJ; Tallon D; Lewis G; Peters TJ; Hollingworth W; Round J; Burns A; Chew-Graham CA; Anderson IM; Shepherd T; Campbell J; Dickens CM; Carter M; Jenkinson C; Macleod U; Gibson H; Davies S; Wiles NJ
    BMJ; 2018 Oct; 363():k4218. PubMed ID: 30381374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antidepressant augmentation with anti-inflammatory agents.
    Andrade C
    J Clin Psychiatry; 2014 Sep; 75(9):975-7. PubMed ID: 25295422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antidepressant combinations: widely used, but far from empirically validated.
    Thase ME
    Can J Psychiatry; 2011 Jun; 56(6):317-23. PubMed ID: 21756445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An episode level evaluation of the treatment journey of patients with major depressive disorder and treatment-resistant depression.
    Wu B; Cai Q; Sheehan JJ; Benson C; Connolly N; Alphs L
    PLoS One; 2019; 14(8):e0220763. PubMed ID: 31393922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors.
    Whyte EM; Basinski J; Farhi P; Dew MA; Begley A; Mulsant BH; Reynolds CF
    J Clin Psychiatry; 2004 Dec; 65(12):1634-41. PubMed ID: 15641868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Efficacy and Safety of Aripiprazole Versus Bupropion Augmentation in Patients With Major Depressive Disorder Unresponsive to Selective Serotonin Reuptake Inhibitors: A Randomized, Prospective, Open-Label Study.
    Cheon EJ; Lee KH; Park YW; Lee JH; Koo BH; Lee SJ; Sung HM
    J Clin Psychopharmacol; 2017 Apr; 37(2):193-199. PubMed ID: 28129308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
    McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
    Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.